Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 39-43, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jalanko, A.
Right arrow Articles by Soderlund, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jalanko, A.
Right arrow Articles by Soderlund, H.

Clinical Chemistry, Vol 38, 39-43, Copyright © 1992 by American Association for Clinical Chemistry

Screening for defined cystic fibrosis mutations by solid-phase minisequencing

A Jalanko, J Kere, E Savilahti, M Schwartz, AC Syvanen, M Ranki and H Soderlund
Orion Corp., Orion Pharmaceutica, Biotechnology, Helsinki, Finland.

We have developed a rapid method for the quantitative detection of point mutations and deletions. In this minisequencing method, enzymatically amplified DNA, 5'-biotinylated in one strand, is bound to a solid phase and denatured. A detection primer, constructed to end immediately before the mutation, is annealed to the immobilized single- stranded template and elongated with a single, labeled deoxynucleoside residue. We have applied the solid-phase minisequencing method to the detection of the major mutation, delta F508, causing cystic fibrosis (CF). In the presence of the allele with the delta F508 mutation, [3H]dTTP is incorporated; with the nonmutated allele, [3H]dCTP is incorporated. Thus, samples from heterozygous individuals allow the incorporation of both labels. The method was evaluated by analyzing 59 coded DNA specimens collected from 20 Finnish CF patients and their parents. The ratio of [3H]C to [3H]T gave unambiguously the allele combination. The solid-phase minisequencing method was also applicable to the analysis of three CF mutations simultaneously, i.e., delta F508, G542X, and G551D. We conclude that the microtiter-plate-based minisequencing test is an accurate method for the screening of defined sequence alterations in the CF gene.


The following articles in journals at HighWire Press have cited this article:


Home page
 Antimicrob. Agents Chemother.Home page
C. Howard, A. van Daal, G. Kelly, J. Schooneveldt, G. Nimmo, and P. M. Giffard
Identification and Minisequencing-Based Discrimination of SHV {beta}-Lactamases in Nosocomial Infection-Associated Klebsiella pneumoniae in Brisbane, Australia
Antimicrob. Agents Chemother., March 1, 2002; 46(3): 659 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Braun, D. P. Little, and H. Koster
Detecting CFTR gene mutations by using primer oligo base extension and mass spectrometry
Clin. Chem., July 1, 1997; 43(7): 1151 - 1158.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.